Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2016 08:30 ET | Source: Chimerix, Inc.

Chimerix to Present at the Barclays Global Healthcare Conference

DURHAM, N.C., March 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that Linda M....
March 01, 2016 08:00 ET | Source: Chimerix, Inc.

Chimerix to Present at Cowen and Company 36th Annual Health Care Conference

DURHAM, N.C., March 01, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M....
February 29, 2016 07:30 ET | Source: Chimerix, Inc.

Chimerix Announces Fourth Quarter and Full Year 2015 Financial Results

- Company to hold conference call at 8:30am ET today -- Survival and other key data from AdVise and matched controls to be reviewed with regulators in Summer 2016 - DURHAM, N.C., Feb. 29, 2016 ...
February 22, 2016 16:05 ET | Source: Chimerix, Inc.

Chimerix to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016

DURHAM, N.C., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced...
February 20, 2016 21:15 ET | Source: Chimerix, Inc.

Chimerix Announces Presentation of Detailed Results From Phase 3 SUPPRESS Trial at BMT Tandem Meetings

Brincidofovir Shows On-Treatment Antiviral Effect in HCT Setting Despite Trial Not Meeting Primary Endpoint Company to Host Conference Call on February 22 at 8:00 a.m. EST to Provide...
February 16, 2016 08:00 ET | Source: Chimerix, Inc.

Detailed Results From SUPPRESS Trial of Brincidofovir to be Presented at BMT Tandem Meetings

DURHAM, N.C., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that...
February 08, 2016 14:03 ET | Source: Chimerix, Inc.

Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox

DURHAM, N.C., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today presented positive...
January 05, 2016 08:30 ET | Source: Chimerix, Inc.

Chimerix to Present at the 34th Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M....
December 28, 2015 07:30 ET | Source: Chimerix, Inc.

Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir

- SUPPRESS Did Not Achieve Primary Endpoint for Prevention of Clinically Significant CMV Infection After HCT - - Detailed Data Analysis to Follow - - Company to Hold Conference Call Today at...
November 24, 2015 08:30 ET | Source: Chimerix, Inc.

Chimerix to Present at the 27th Annual Piper Jaffray Healthcare Conference

DURHAM, N.C., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle...